Contact us


Rituximab Plus Lenalidomide Combination Therapy for Patients With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma (AUGMENT)

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma (The “AUGMENT” Study)

For more information, please visit

Patient Population Investigational Product(s) Phase Status
Relapsed/Refractory Follicular Lymphoma Lenalidomide III Open and Accruing